India, Feb. 25 -- Ahmedabad-based Zydus Lifesciences plans to launch Semaglutide Injection under the brand names -SEMAGLYNTM, MASHEMATMand ALTERMETM, upon Semaglutide patent expiry in India.

The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of Type 2 Diabetes Mellitus and Obesity.

A critical differentiator of Zydus' Semaglutide offering will be its novel, indigenously developed drug-delivery system. Unlike existing treatments that require patients to purchase multiple single-dose pens as they titrate their dosage, Zydus plans to introduce an innovative, adjustable single-pen device. This technology allows patients to seamlessly select and...